Sientra® Appoints Charlie Huiner as Chief Strategy and Corporate Development Officer


SANTA BARBARA, Calif. (April 8, 2014) – Sientra, Inc. (Sientra), a privately-held medical aesthetics company serving plastic surgeons exclusively, today announced the appointment of Charlie Huiner as Chief Strategy and Corporate Development Officer.

Huiner brings to Sientra a 20-year successful business development track record with more than 11 years of medical technology experience. Huiner spent 3 years at INAMED (now Allergan Medical) developing his medical aesthetics experience, serving in roles of increasing responsibility that spanned corporate strategy, business development, corporate communications and investor relations. At INAMED Huiner was part of the core team responsible for negotiating and acquiring the rights to JUVÉDERM®, now the leading dermal filler on the market globally, and expanding the global rights to the DYSPORT® botulinum toxin A cosmetic injectable. Huiner was also part of the senior transaction team that executed the $3.3 billion sale of INAMED to Allergan Medical.

"I am thrilled to have Charlie rejoin me at Sientra in a key executive role where he brings the benefits of his medical technology industry experience coupled with his unique mix of transactional, marketing, communications and strategy development expertise to lead Sientra's strategic initiatives," said Hani Zeini, Sientra's Founder and CEO. "In the context of Sientra's rapid growth, it is imperative that we deliberately plan and execute a strategic roadmap and product development pipeline that keeps us closely aligned with the needs of the plastic surgeons that we serve and fulfills Sientra's mission to achieve significant transformation and value creation in our chosen markets."

Prior to joining Sientra, Huiner served as Vice President of Business Development and Marketing at InTouch Health. During his six-year tenure at InTouch Health Huiner conceived of, built and led the Company's B-to-B surgical collaboration business, growing it to over 10% of the Company's revenue in its first 2 years and identifying, nurturing and closing significant, multi-year sales contracts. Additionally Huiner helped build a high performance marketing team and communications program and was a key contributor to the successful launch of InTouch Health's RP-VITA® robotic telemedicine platform. His extensive business development, marketing and strategic partnership expertise is grounded by early career experience in operating and investing roles with Security Capital Group (now GE Capital) and ProLogis. He began his career as an M&A financial analyst for NatWest USA. Huiner earned a BA in History from Williams College, and an MBA in finance and marketing from Northwestern University's Kellogg School where he concentrated in healthcare management.

* The third-party trademarks used herein are trademarks of their respective owners.

Nasdaq: SIEN

Stock Quote: NASD

$0.84 -0.04
Volume 452,889
Previous Close 0.88
Intraday High 0.89
Intraday Low 0.81
Pricing delayed 20 minutes
Price Change % Change -4.95% 52 Week High 9.14 52 Week Low 0.80 Today's Open 0.89 Jun 29, 2022 04:00 PM

Investor Contact

Sientra Investor Relations